Esophageal adenocarcinoma

This clinical trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or esophageal cancer live longer. The study includes 224 adults whose cancer has a specific marker (PD-L1 CPS…

This Phase 2 trial is testing a new drug called denikitug, alone or combined with other cancer drugs, in 120 people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. The main goal is to see if the drug …

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…

Researchers are testing whether adding an experimental drug called 2141-V11 to standard immunotherapy is safe for people with advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma. Participants receive injections of 2141-V11 directly into their tumors along wi…

This study compares two standard approaches for Barrett's esophagus with low-grade dysplasia: regular monitoring with biopsies (surveillance) versus a procedure to remove or burn away precancerous cells (endoscopic eradication therapy). Researchers want to find out which method i…

This early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…

This clinical trial is looking at the best timing for local treatments like surgery or radiation in people with esophageal or stomach cancer that has spread to only a few spots. All participants first get 4 months of standard drug therapy. Then, depending on their response, they …

This Phase 3 trial is testing whether a new targeted drug called sonesitatug vedotin, combined with chemotherapy (capecitabine) and possibly an immunotherapy (rilvegostomig), can help people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specifi…

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This study compares two drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that hasn't been treated yet. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combo works b…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…

This study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. About 210 participants will receive either an experimental antibody-drug conjugate plus chemotherapy, or a stand…

This study tests whether a stronger chemotherapy mix (mFOLFIRINOX) works better than the standard mix (FOLFOX) for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. Some participants also receive the immunotherapy dru…

This trial tests whether adding a personalized, ultra-precise radiation technique called PULSAR to standard chemotherapy and immunotherapy is safe for people with esophageal or gastro-esophageal junction cancer. The study aims to find the best radiation dose that can be given wit…

This study tests new experimental drugs combined with standard chemotherapy and immunotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery or has spread. About 160 participants will receive the combination to …

This early-stage trial is testing a new treatment called DISP-10 for people with advanced gastrointestinal cancers, including colorectal and stomach cancers. The treatment combines a virus (DV-10) with specially engineered immune cells (CAR T cells) to attack cancer. The study ai…

This early-phase trial is testing a new drug called NRM-823, alone or with immunotherapy, in people with advanced solid tumors like lung, ovarian, or breast cancer that haven't responded to standard treatments. The study aims to see if the drug is safe and tolerable. About 150 pa…

This study tests whether freezing cancer cells with liquid nitrogen before chemotherapy can improve outcomes for people with advanced esophageal cancer. About 40 adults will be randomly assigned to receive either the freezing treatment plus chemotherapy or chemotherapy alone. The…

This study tests several new drug combinations given before and after surgery for stomach or esophageal cancer. About 100 people with resectable tumors will receive these treatments to see if they are safe and can shrink or eliminate the cancer. The goal is to improve outcomes by…

This study tests a new experimental drug, PF-08634404, combined with chemotherapy in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new…

This study is for people with advanced gastrointestinal cancers that are growing despite immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiati…

This phase 2 trial tests whether obeticholic acid can reduce damage from bile acids in people with Barrett's esophagus, a condition that can lead to esophageal cancer. About 30 adults with Barrett's esophagus will take the drug or a placebo for 6 months. Researchers will measure …

This early-phase trial tests a new drug called NBTXR3, which is injected into the tumor and activated by radiation to destroy cancer cells. It is given alongside standard chemotherapy for people with stage II–III esophageal adenocarcinoma. The main goals are to find the safest do…

This treatment program tests a personalized cell therapy for people with advanced pancreatic or colorectal cancers that have a specific genetic mutation (KRAS G12D). Patients' own immune cells are collected, genetically engineered to recognize and attack the cancer, and then infu…

This trial compares two liquids—hyaluronic acid and hydroxyethylamide—used to lift early-stage esophageal tumors before endoscopic removal. Doctors inject one of these solutions under the cancer to create a cushion, making it safer and easier to cut out. The study measures how mu…

This early-stage trial is testing an experimental drug called CHS-114 combined with the immunotherapy toripalimab, with or without standard chemotherapy, in 154 people with advanced or metastatic solid tumors. The main goal is to see if the combination is safe and to get an early…

This early-phase trial is testing whether a single dose of two immunotherapy drugs (tremelimumab and durvalumab) can increase cancer-fighting immune cells inside tumors. It includes 34 people with untreated, non-metastatic stomach or esophageal cancers that have an ARID1A gene mu…

This early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…

This study tests a new drug called DR30206 combined with standard treatments for people with advanced or spreading gastrointestinal cancers, like colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. About 186 adults in China will take part.

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This phase 2 trial is testing a combination of three chemotherapy drugs plus immunotherapy as a first treatment for advanced esophageal and gastric cancer. For patients with HER2-positive tumors, the targeted drug trastuzumab is also added. The study aims to see if this mix is mo…

This study tests a new experimental drug called PLX-61639 for people with advanced solid tumors that have a specific genetic change (SMARCA4 mutation) and have stopped responding to standard treatments. The drug is taken as a daily pill and aims to shrink or control the cancer. A…

This early-stage trial tests a new treatment for advanced esophageal cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (CAR-NK cells) from donated cord blood that are designed to recognize and attack cancer cells carrying tw…

This Phase 2 trial tests whether adding the experimental drug givastomig to standard immunotherapy and chemotherapy can help people with advanced stomach or esophageal cancer live longer without their cancer growing. About 180 adults whose tumors have certain proteins (CLDN18.2 a…

This study tests IKS014, a drug designed to seek out and destroy HER2-positive cancer cells, in people with advanced solid tumors like breast, stomach, and gastroesophageal cancers. The main goals are to find the safest dose and check for early signs of tumor shrinkage. About 165…

This Phase 2 trial tests whether adding the immunotherapy drug ivonescimab to standard chemotherapy can improve tumor shrinkage in people with advanced or metastatic stomach or gastroesophageal cancer. About 88 participants will receive treatment every two weeks. The main goal is…

This phase 2 study tests a new approach for people with advanced stomach, esophageal, or gastroesophageal junction cancer that is either PD-L1-negative or has stopped responding to immunotherapy. Participants receive injections of a cancer-killing virus (OBP-301) directly into th…

This study is for people with stage I to III esophageal or gastroesophageal junction cancer. It tests whether giving a shorter, higher-dose radiation treatment along with chemotherapy (FOLFOX) before surgery can kill more cancer cells. The goal is to see if this approach leads to…

This study is for people with esophageal or stomach cancer that has spread to 3 or fewer places in the body. It compares standard chemotherapy alone to chemotherapy plus radiation or surgery to the main tumor and those spots. The goal is to see if adding local treatment helps peo…

This early-stage trial is testing a new drug called TGW101 in people with advanced solid tumors that have not responded to other treatments. TGW101 is given in two parts: an antibody-drug conjugate and a chemical trigger that activates it. The main goal is to check safety and fin…

This early-stage study tests an experimental drug called TJ033721 (givastomig) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processe…

This study tests an experimental drug called AZD5863 in adults with advanced stomach, gastro-esophageal junction, pancreatic, or esophageal cancers that have spread. The drug is a bispecific antibody designed to bring immune cells close to cancer cells to attack them. The main go…

This early-phase trial is testing a new type of immunotherapy called CAR T-cells for people with a specific kind of stomach and esophageal cancer that has spread to the lining of the abdomen. The treatment involves collecting a patient's own immune cells, modifying them in a lab …

This Phase 3 trial tests whether adding fruquintinib to the standard drug trifluridine/tipiracil helps people with advanced stomach or gastro-esophageal cancer live longer. About 324 participants who have already tried at least two prior treatments will receive either the combo o…

This early-phase study tests a new approach for people with a type of esophageal cancer. Participants receive standard chemotherapy followed by a special MRI-guided radiation treatment. The main goal is to find the safest radiation dose and see if this combination can better cont…

This study tests whether combining the targeted drug cabozantinib with immunotherapy drugs (durvalumab, with or without tremelimumab) is safe and effective for people with advanced stomach, esophageal, liver, or colorectal cancer. About 117 adults with stage 3 or 4 disease that c…

This phase II trial is testing a rotating schedule of two chemotherapy regimens (FOLFOX and FOLFIRI), with or without the immunotherapy nivolumab, in 38 people with advanced HER2-negative gastric or esophageal cancer. The goal is to see if this approach improves tumor shrinkage a…

This study tests adding propranolol, a blood pressure medicine, to standard chemoradiation for people with esophageal adenocarcinoma. About 106 participants will receive the combination to see if it is safe and helps control the disease longer. The goal is to improve treatment wi…

This study tests whether giving two different chemotherapy regimens one after the other before surgery can help people with esophageal cancer that has spread to nearby lymph nodes. About 216 adults with resectable cancer will receive either FLOT followed by CROSS or CROSS followe…

This early-phase trial tests a new combination of the immunotherapy drug tislelizumab plus standard chemotherapy (FLOT) given before surgery for people with stomach, esophageal, or gastroesophageal junction cancer that can be removed. The goal is to see if this longer pre-surgery…

This early-stage study tests whether combining two drugs (sacituzumab govitecan and capecitabine) is safe for people with advanced gastrointestinal cancers that have stopped responding to standard treatments. About 20 adults with stomach, colorectal, or pancreatic cancer will tak…

This phase 2 trial is testing whether adding propranolol, a common beta-blocker used for heart conditions, to standard chemotherapy and pembrolizumab (an immunotherapy) can improve treatment response in people with advanced esophageal or gastroesophageal junction cancer that cann…

This phase II trial tests whether adding itraconazole, a common antifungal medication, to standard chemoradiation can improve outcomes for people with resectable esophageal cancer. About 78 participants will receive itraconazole before and after standard treatment, then undergo s…

This program provides early access to an experimental drug called AVM0703 for people with various solid tumors and blood cancers, including hard-to-treat types like glioblastoma and metastatic breast cancer. It is available to patients in the US whose doctor requests it. So far, …

This study aims to see if a new office-based test (EsoCheck balloon and EsoGuard lab test) can accurately detect Barrett's esophagus in people who do not have chronic heartburn. Barrett's esophagus is a condition that can lead to esophageal cancer, but it is often missed in peopl…

This study is testing a simple breath test to help detect gastrointestinal cancers—including cancers of the esophagus, stomach, pancreas, liver, and bowel—at an earlier stage. The test measures tiny molecules in exhaled breath that may be linked to these cancers. Participants pro…

This trial compares two ways to sample tissue in people with Barrett's esophagus, a condition that raises the risk of esophageal cancer. The standard method takes four small tissue samples every 2 centimeters, while the newer method uses a brush to collect cells over a wider area…

This study is testing a blood test that looks for tiny bits of cancer DNA (ctDNA) in people with esophageal, gastric, or pancreatic cancer. The goal is to see if it can find signs of cancer coming back or getting worse earlier than current methods. About 34 participants will give…

This trial is testing a new, less invasive way to detect Barrett's esophagus, a condition that can lead to esophageal cancer. Participants swallow a capsule attached to a string that expands into a sponge in the stomach, collecting cells as it is pulled back up. The goal is to se…

This study tests a new way to find early signs of esophageal cancer in people with Barrett's esophagus. Participants will receive two fluorescent dyes (bevacizumab-800CW and cetuximab-800CW) either by mouth or directly on the esophagus before a standard endoscopy. The goal is to …

This study is testing a new, less invasive way to diagnose Barrett's esophagus and esophageal cancer using a sponge capsule that patients swallow. The sponge collects cells from the esophagus, which are then analyzed for signs of disease. Researchers will enroll 1,550 people aged…

This study tests a special dye and imaging system to help surgeons see colorectal, pancreatic, esophageal, and stomach cancers during surgery. About 66 adults scheduled for cancer surgery will receive the dye, and the imaging system will check if it lights up cancer tissue. The g…

This study tests whether adding the antifungal drug itraconazole to standard ablation therapy can prevent esophageal cancer in people with high-risk Barrett's esophagus. About 64 participants will receive either itraconazole or a placebo alongside their usual endoscopic ablation.…

This trial tests whether giving radiation in tiny pulses (pulsed low-dose-rate) instead of the standard continuous dose can lower the risk of severe esophagitis—painful inflammation of the swallowing tube—during chemoradiation for esophageal cancer. About 50 people with stage II …

This study looks at whether people with certain cancers prefer getting their immune therapy as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 880 adults who are already eligible for standard treatments like nivolumab or pembrolizumab will …

This study tests a small device called Seismofit that sticks to the chest and measures heart vibrations to estimate fitness in under three minutes. Researchers want to see if it can predict complications like pneumonia and hospital stay length in 164 oesophageal cancer patients u…

This study reviews the medical records of about 4000 people who had surgery for esophageal cancer. The goal is to see how the amount of cancer left at the edges of the removed tissue affects how long people live. No new treatments are given; the study only looks at past informati…

This research study is investigating how genetics and environmental factors contribute to the development of Barrett's esophagus and esophageal adenocarcinoma, a type of cancer. Researchers will collect samples from the esophagus using a non-endoscopic balloon capsule device, whi…

This study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …

This study looked at whether low oxygen levels after esophageal cancer surgery increase the chance of a leak where the esophagus is reconnected. Researchers reviewed records of 2,083 patients, comparing those with low oxygen to those with normal levels. The goal was to see if cor…

This study is looking at whether a blood test (liquid biopsy) can find tiny bits of cancer DNA left behind after treatment for esophageal cancer. Researchers will collect blood samples from 248 patients before, during, and after standard treatment. The goal is to see if this test…

This study is creating a database to track how people with esophageal or gastroesophageal junction cancer that has spread to only a few places (like the liver or lymph nodes) are treated in real-world settings. Researchers will collect information from 50 participants to see whic…

This pilot study is testing whether cells collected by brushing the esophagus during a routine endoscopy can be genetically analyzed to better predict cancer risk in people with Barrett's esophagus. Researchers will collect brush samples, biopsies, and blood from 50 patients, the…

This study tests whether different levels of exercise before surgery can increase immune cells inside oesophageal cancer tumors. Researchers will measure changes in fitness and immune response in 50 adults with resectable oesophageal adenocarcinoma. The goal is to find the best e…

This study is a large registry that will collect information from about 1,900 people with advanced cancer of the esophagus or stomach who are receiving palliative treatment in Germany. The goal is to understand what treatments are actually used in everyday practice and how patien…

This pilot study aims to see how common Barrett's esophagus is in people with eating disorders who have been purging (vomiting or ruminating) for at least 5 years. Researchers will use a simple, non-endoscopic device called EsoGuard to collect cell samples from the esophagus. The…